Crowd of sperm at high magnification.

The 1/2 life Ratio compares the value human reproductive tissue, specifically the market value of sperm to the market value of Ova. While the market demand for each type of tissue remains largely equivalent–approximately 30% of infertility is attributable to men, 30% to women, and the rest is unknown–the current divergence is just under $40000 per viable reproductive cell. That is, it ‘costs’ ova donors about that much per viable ova, while sperm donors come out in front(by about 0.006 cents per viable cell). The ratio uses quantitative risk analysis to compare the short term, longterm and unknown health risks, in addition to the risk of future ligtigation.Cost benefit and fixed effects analysis are also applied to account for the differences in the tissue perishability; the mass in grams; the labor costs (time spent); the window of opportunity and opportunity costs; the presence, or absence, and results of psychological tests and interviews (used primarily with ova donors), in addition to other variables. This indicator shows that new ART (Assistive Reproductive Technology) technologies, can reproduce very familiar gender inequities.